Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCARCE: SBRT + Cadonilimab in Advanced Solid Tumors
NCT05915481Phase 2Unknown
- Sponsor
- Peking University Third Hospital
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in solid tumor, sponsored by Peking University Third Hospital. Status: unknown.
02
Drugs
cadonilimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05915481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05915481.